‘This intermediate-size expanded access protocol plans to treat approximately 50 children or adolescents, male and female, with MIS-C associated with COVID-19. Participants who are 2 months to 17 years of age, inclusive, will be enrolled at multiple clinical sites across the United States.’
‘The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.’
OH LORDY!
Multisystem Inflammatory Syndrome in Children (MIS-C), page-2
-
- There are more pages in this discussion • 163 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.070(6.57%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | 99.5¢ | $3.980M | 3.944M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 56239 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 103125 | 2 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |